India Diabetes Market

Business news, market intelligence, and global industry analysis.

The Latest

Equinor activates ultra-deepwater drilling with the Valaris DS-17 drillship at Raia as Brazil's natural gas supply gap draws international capital.

Equinor (EQNR) activates $9bn Raia drilling campaign in Brazil as deepwater gas race intensifies

Representative image of AI-powered contract review software in a corporate legal workflow, illustrating how Docusign’s new AI contract review assistant could help streamline agreement analysis, redlining, and contract negotiations.

Docusign (NASDAQ: DOCU) pushes deeper into legal workflow automation with AI contract review launch

Flint Development wins Spotsylvania County approval for Patriot 95 logistics facility in Thornburg, VA

Arbor Energy signs 5 GW deal with GridMarket to supply zero-emission baseload power from 2029

Representative image of semaglutide injection pens and vials, highlighting Glenmark Pharmaceuticals’ GLIPIQ launch in India as the generic GLP-1 diabetes treatment market begins following patent expiry.

Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts

Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 21, 2026